ASND - Ascendis Pharma A/S
| Previous Close | 120.89 |
| Open | 121.02 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 120.98 - 128.43 |
| 52 Week Range | 53.21 - 133.96 |
| Volume | 322,434 |
| Avg. Volume | 289,048 |
| Market Cap | 6.027B |
| Beta (3Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.87 |
| Earnings Date | Aug 29, 2017 - Sep 4, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 165.12 |
- Insider Monkey•8 days ago
Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of ASND earnings conference call or presentation 30-May-19 8:30pm GMT
Q1 2019 Ascendis Pharma A/S Earnings and Business Update Call
- GlobeNewswire•19 days ago
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature.
- ACCESSWIRE•19 days ago
Ascendis Pharma A/S to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 30, 2019 / Ascendis Pharma A/S (NASDAQ: ASND ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 30, 2019 at 4:30 PM Eastern ...
- GlobeNewswire•29 days ago
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced preliminary results from the phase 3 fliGHt Trial of TransCon Growth Hormone (hGH). The results indicated treatment with TransCon hGH was safe and well-tolerated in subjects with pediatric growth hormone deficiency (GHD) who were previously treated with commercially-available daily growth hormone therapies.
- GlobeNewswire•last month
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, May 30, 2019 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2019 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- GlobeNewswire•last month
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- Insider Monkey•last month
Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap
Sohn Conference is my favorite hedge fund event. I haven't missed an event since 2013. This doesn't mean that every stock pitched at the conference is a great investment opportunity and will beat its benchmark. A few weeks ago we took a look at the performance of the stocks pitched at the 2018 Sohn Conference […]
- Simply Wall St.•last month
What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ascend...
- Insider Monkey•2 months ago
Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
Is Ascendis Pharma A/S (NASDAQ:ASND) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
- Insider Monkey•2 months ago
Glenview Capital Management’s Stock Pitches At 2018 Sohn Conference
Glenview Capital Management is a New York City-based hedge fund, that was launched 18 years ago by Larry Robbins, who previously worked as a trader for billionaire Leon Cooperman’s Omega Advisors. The fund posted return of 301% after fees and expenses for the first decade of its existence, even though 2008 posed too many difficulties […]
- GlobeNewswire•2 months ago
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
COPENHAGEN, Denmark, April 24, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
- Insider Monkey•2 months ago
Joseph Jolson’s Harvest Capital Strategies’ Return, AUM, and Holdings
Harvest Capital Strategies is a San Francisco-based hedge fund that mainly focuses on private equity and venture capital, middle-market lending and on equity hedge funds. It was founded back in 1999, and it operates as a subsidiary of JMP Group Inc. Joseph Jolson, the fund’s CEO, co-founded JMP Group and is its CEO and the […]
- Insider Monkey•2 months ago
Best Stock Pick From The 2018 Sohn Conference (Part II)
Read the beginning of this article here. Nathaniel August recommended a position in Peabody Energy (NYSE:BTU) which “is the largest and least expensive way to participate in the coal market” according to this fund manager. Unfortunately the stock lost more than 26% since August’s recommendation. David Einhorn recommended a short position in Assured Guaranty (NYSE:AGO) due […]
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT
Full Year 2018 Ascendis Pharma A/S Earnings Call
- Insider Monkey•2 months ago
What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?
It has been almost a year since the last annual Sohn Conference held in New York, and we thought it would be interesting to take a look at how some of the stock pitches presented there have performed since. Today, we are going to take a look at Light Street’s Glen Kacher’s best idea from […]
- Insider Monkey•2 months ago
Mangrove Partners’ Nathaniel August’s Best Idea At 2018 Sohn Conference
Nathaniel August’s Mangrove Partners is known for outperforming the market very often; in the first three years since its launching (2010), the fund brought an astonishing return of 44% annually. It continued with its strong performance in the next year, delivering 26.6%. In spite of losing around 1.9% in 2015, the fund compensated for it […]
- Insider Monkey•2 months ago
Sarissa Capital Management Hires New President
Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%. Just for the comparison, an average activist hedge fund reported a loss of 11% in the same period, and the S&P 500 lost 4.4%. Even over the last three years, the fund […]
Motley Fool•2 months agoAscendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call Transcript
ASND earnings call for the period ending December 31, 2018.
- GlobeNewswire•2 months ago
Ascendis Pharma A/S Reports Full Year 2018 Financial Results
– Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated – – Phase 3 heiGHt Trial results showcase potential of TransCon™.
- ACCESSWIRE•2 months ago
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 ...
- GlobeNewswire•3 months ago
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
COPENHAGEN, Denmark, March 27, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
- Zacks•3 months ago
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
- GlobeNewswire•3 months ago
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism (HP) on patients in a poster at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. The study found that, despite treatment with current therapies, 100 percent of patients experienced physical impact, psychological impact, and interference with daily life, reflecting a substantial illness burden from HP. “I have lived with HP for over 25 years and have personally experienced how this debilitating disease affects all areas of life - physical, emotional and social,” said Deb Murphy, President of the HypoPARAthyroidism Association, Inc. “This study highlights that currently available therapies are still not enough.
- GlobeNewswire•3 months ago
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced top-line results from its pivotal phase 3 heiGHt Trial were presented at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. Trial results demonstrated that TransCon Growth Hormone (hGH) administered once-weekly to children with pediatric growth hormone deficiency (GHD) had comparable safety and tolerability to daily Genotropin®, with a significantly greater increase in annualized height velocity over the one-year study period.
